Kinase targets in CNS drug discovery

Area of Science:

• Pharmacology
• Neuroscience
• Drug Discovery

Background:

• Kinases are crucial signaling proteins, historically considered difficult to drug but now recognized as important therapeutic targets.
• Over 40 kinase inhibitors, mostly small molecules, are FDA-approved, primarily for cancer treatment.
• Currently, no kinase inhibitors are approved for central nervous system (CNS) disorders, highlighting an unmet medical need.

Purpose of the Study:

• To review selected kinase targets relevant to CNS disorders.
• To highlight brain-permeable small-molecule kinase inhibitors with preclinical proof-of-concept efficacy.
• To discuss challenges in developing CNS-targeted kinase inhibitors.

Main Methods:

• Literature review of kinase inhibitors for CNS disorders.
• Identification of brain-permeable small-molecule inhibitors.
• Analysis of preclinical efficacy data.
• Discussion of pharmacokinetic and pharmacodynamic challenges.

Main Results:

• Several kinase targets for CNS disorders have been identified.
• Brain-permeable small-molecule inhibitors targeting these kinases have shown preclinical efficacy.
• Demonstrated proof-of-concept in preclinical models for various CNS conditions.

Conclusions:

• Kinase inhibitors represent a promising therapeutic strategy for CNS disorders.
• Overcoming blood-brain barrier penetration and ensuring target selectivity are critical for clinical success.
• Further research into CNS-penetrant kinase inhibitors is warranted.